News

News 30.09.2025 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced that it has successfully completed enrollment in the Phase I clinical trial of V-212, a peptide-based, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. “Completing enrollment in this Phase I trial marks a significant milestone for V-212,”...

News 29.09.2025 DINAMIQS, a Siegfried company (SIX: SFZN), today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. As part of this facility, new lab...

News 29.09.2025 AL-S Pharma announced today that it has appointed Angela Genge, MD, Professor of Neurology at McGill University in Montreal, as Chief Medical Officer (CMO). With a distinguished record in amyotrophic lateral sclerosis (ALS) research and the Head of ALS Global Centre of Excellence for Research and Patient Care at McGill,...

News 25.09.2025 „If adidas, Target & Zalando can rethink plastics, what’s stopping the rest?” 👟✨ We are proud to see leading players taking real action against the massive environmental impacts of footwear production. Their commitment to testing and validating bio-based alternatives shows that disruptive innovation requires courage and collaboration. 💡 It’s inspiring to be...

News 23.09.2025 CINCINNATI, September 22, 2025 — Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has  signed a licensing agreement, with Immunovia...